tbuckley/cabot-search huggingface dataset:
Supportive care needs among Mexican young women with breast cancer.
Authors: C. Lizette Galvez, Cynthia Villarreal-Garza, Alejandro Mohar
Journal: Journal of Clinical Oncology (2017)

e21552 Background: Despite high rates of breast cancer (BC) in young Mexican women, information about their particular needs and concerns is largely unknown. Understanding the patients individual needs in a population with unique socio-cultural features is essential to guide supportive care and improve their quality of life. We aim to describe the unmet needs of Mexican young women with breast cancer (YWBC). Methods: A cross-sectional study including women with stage I-III BC aged 40 years or younger at diagnosis was conducted at the National Cancer Institute in Mexico City. YWBC were invited to complete the Supportive Care Needs Survey, Short Form-34 (SCNS-SF34), a comprehensive tool that measures the perceived unmet needs of cancer patients. The survey was previously adapted and validated in our population for its use. Results: 81 consecutive patients with median age at diagnosis of 35.09 (SD 3.9) years were included. 45.7% were married and 29.2% completed secondary school. 92.6% had stage II-III BC. 70.4% were undergoing active treatment and 29.6% were either on hormonal therapy or surveillance. From a total standardized score of 100, the health systems and information domain had the highest mean score (39.3), followed by the psychological domain (36.3). The sexuality domain had the lowest mean score (27). The highest ranked items of unmet needs (by mean crude score) were: to be informed about cancer is under control or diminishing (2.9), to be informed about things you can do to help yourself get well (2.8), lack of energy and fatigue (2.7), and fear about the cancer spreading (2.7). Perceived needs among patients undergoing active treatment were greater compared to those in follow-up (z = -2.390 p = 0.017), predominantly in the sexuality domain (z = -2.084 p = 0.037). Conclusions: Mexican YWBC have specific needs that are currently not systematically addressed. The predominant unmet need regarding health systems and information should be a priority. Further research to understand the needs and concerns of this unique and understudied patient population will aid tailor clinical interventions and supportive care.
TCT-867 Polymer-free sirolimus-eluting stents in an elderly and octogenarian all-comer population
Authors: Behrouz Kherad, Matt Waliszewski, Muhamad Ali SK Abdul Kader, Liew Houng Bang, Fernando Lozano, Burkert Pieske, Markus Florian Krackhardt
Journal: Journal of the American College of Cardiology (2018)
Online yoga as a non-pharmacologic symptom management approach in myeloproliferative neoplasms.
Authors: Jennifer Huberty, Ryan Eckert, Krisstina L. Gowin, Brenda F. Ginos, Heidi E. Kosiorek, Amylou C. Dueck, Linda Larkey, Ruben A. Mesa
Journal: Journal of Clinical Oncology (2017)

e21704 Background: Patients with myeloproliferative neoplasms (MPN) have difficult symptom burden (i.e. fatigue, pruritus, night sweats) not resolved by current medical therapies including jak inhibitor therapy. We hypothesize that on-line (at home) yoga might alleviate MPN symptoms and complement medical therapy. Methods: MPN patients, recruited by social media, were asked to complete 60 min/week of online yoga (designed for MPN patients) for 12 weeks and completed online self-report surveys (weeks 0,7,12 and 16) on participation (Qualtrics), disease features, and symptom burden (MPN Symptom Assessment Form; NIH PROMIS measures of pain, anxiety, depression, sleep, and sexual function). Results: Two hundred and forty-four MPN patients completed the eligibility survey, 134 were eligible, 55 completed the informed consent, and 38 MPN patients completed the 12-week intervention. The majority of participants were diagnosed with either PV (n = 16) or ET (n = 16), with MF being less common (n = 6). Approximately 37% (n = 14) of study participants averaged ≥60 min/week of yoga (i.e., demand). Yoga participation averaged 50.8±36.2 min/week. Overall, 68% of participants were satisfied with online yoga and 75% felt that is was helpful for coping with MPN-related symptoms (i.e., acceptability, practicality). Additionally, 75% of participants felt safe from injury while participating in online yoga. Only one adverse event was reported (irritated enlarged spleen). From week 0 to week 12 (n = 38), there were significant improvements in total symptom burden (effect size [ES] in standard deviation units = -0.36, p = 0.004), anxiety (ES = -0.67, p = 0.002), depression (ES = -0.41, p = 0.049), sleep (ES = -0.58, p &lt; 0.001), and fatigue (ES = -0.33, p = 0.04). These improvements remained significant at follow-up week 16 (n = 28) for all outcome measures with a trend for maintained fatigue improvement (ES = -0.34, p = 0.06) (see Table 1). There were no significant differences in outcomes between those that averaged &lt; 60 min/week of yoga compared to those that averaged ≥60 min/week of yoga. Conclusions: A 12-week online yoga intervention is feasible (i.e., accepted, practical) for MPN patients and merits a randomized trial as complementary therapy.
Effect of chrysophanol on apoptosis induced by H<sub>2</sub>O<sub>2</sub> in SH-SY5Y cells.
Authors: Si Fuchun, Sun Miao, Si Gao
Journal: Journal of Clinical Oncology (2018)

e24017 Background: Chrysophanol and its derivatives exert a number of biological activities. Especially the anticancer effects of chrysophanol had drawn a lot of attention, with debate on the effect of chrysophanol on apoptosis. The aim of the present study was to investigate whether the concomitant application of chrysophanol affects hydrogen peroxide (H2O2)-induced apoptosis. Methods: SH-SY5Y human neuroblastoma cells were treated with H2O2 with or without preconditioning with chrysophanol. Cell viability was determined using an MTT assay, apoptotic cells were measured with annexin V staining followed by flow cytometry, apoptotic bodies were visualized via DAPI staining and the expression levels of B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X (Bax) were determined using western blotting and reverse transcription-quantitative polymerase chain reaction. Results: The results demonstrated that H2O2 inhibited SH-SY5Y cell proliferation and induced cell apoptosis. Furthermore, western blot analysis results demonstrated that H2O2 reduced the ratio of Bcl-2/Bax and promote the cleavage of procaspase-3. Preconditioning SH-SY5Y cells with chrysophanol alleviated H2O2-induced damage, reversed the effects of H2O2 on the ratio of Bcl-2/Bax and reduced the number of apoptotic cells. Overall, the results of the current study indicated that chrysophanol ameliorated H2O2-induced cell death and protected the cells against apoptosis induced by oxidative stress. Conclusions: The results of the present study may provide novel insights for the application of chrysophanol as a neuronal protective reagents in cancer treatment.
Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials.
Authors: Luis G. Paz-Ares, Kui Shen, Brandon W. Higgs, Chris Morehouse, Naiyer A. Rizvi, Neil Howard Segal, Xiaoping Jin, Yanan Zheng, Rajesh Narwal, Ashok Kumar Gupta, Phillip A. Dennis, Pralay Mukhopadhyay, Koustubh Ranade
Journal: Journal of Clinical Oncology (2017)

3038 Background: Immunotherapies have improved survival in NSCLC but not all pts benefit. Besides baseline PDL1 expression, routinely measured clinical factors may predict clinical outcomes in immunotherapy trials. LM are associated with poor prognosis in melanoma and bladder cancer pts treated with anti-PD1/L1, respectively. We examined correlation between pretreatment LM and survival in D-treated NSCLC pts. Methods: CP1108/NCT01693562 and ATLANTIC/NCT02087423 were nonrandomized phase 1/2 and 2 trials, respectively, of D 10 mg/kg Q2W in advanced NSCLC. As of Oct 24/Jun 3 2016, 304/265 primarily pretreated pts were enrolled in CP1108/ATLANTIC Cohort 2. Cox proportional hazards analysis was conducted, first among LM+/− pts, then LM+/− and PDL1 high/low pts. Both models accounted for tumor stage, ECOG/WHO PS, histology, sex, age, smoking and PDL1 status. PDL1 high was defined as ≥25% tumor cells immunostained for PDL1 at any intensity. Results: LM absence was a positive independent predictor of OS and PFS in both trials. LM− and PDL1 high or low pts had improved OS and PFS vs PDL1 low/LM+; PDL1 high/LM+ pts had improved PFS vs PDL1 low/LM+. An independent tumor kinetic model indicated LM as a predictive covariate of rapid tumor growth in D-treated pts. Conclusions: LM are associated with shorter survival in D-treated NSCLC pts in 2 trials irrespective of PDL1 status. Clinical trial information: NCT02087423 and NCT01693562. [Table: see text]
Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.
Authors: Yanina Jansen, Elisa A. Rozeman, Marnix Geukes Foppen, Lars Bastholt, Henrik Schmidt, Johannes V. Van Thienen, John B. A. G. Haanen, Leena Tiainen, Inge Marie Svane, Siru Päivikki Mäkelä, Ana Arance, Lise Hoejberg, Marta Nyakas, Oddbjorn Straume, Christian U. Blank, Bart Neyns
Journal: Journal of Clinical Oncology (2017)

9539 Background: PEMBRO improves survival of patients (pts) with advanced melanoma. Optimal duration of treatment in responding pts hasn’t been established. Methods: 12 European hospitals collected data from 509 pts treated with PEMBRO outside an interventional clinical trial. Outcome was evaluated for pts who discontinued PEMBRO in the absence of progressive disease [PD]. Results: After a median follow up of 56 wks [range 1-135], median PFS was 22 wks [95% CI 18-26] and median OS was 70 wks [95% CI 59-81] for the total population. PEMBRO is ongoing in 66 [13%] pts, 344 [68%] pts stopped PEMBRO because of PD, and 99 [19%] pts discontinued PEMBRO without evidence of PD (of which 65 [13%] pts upon pt/MD decision, 26 [5%] pts due to a PEMBRO-related AE of grade &lt; 4 and 8 [2%] pts due to a grade 5 PEMBRO-unrelated AE). Pts discontinuing PEMBRO without PD had a significant [ P &lt;.005] better ECOG PS, less advanced tumor stage, less frequent brain metastases and more often a normal LDH at baseline. There was no significant difference between pts stopping due to AE or upon pt/MD decision. The median time on treatment for the 65 pts who stopped PEMBRO upon pt/MD decision was 55 wks [range 9-112].Their best objective response rate [BORR] was 80% [31 [48%] CR, 21 [32%] PR, 12 [18%]SD, 1[2%]NE]. After a median follow-up of 26 wks [range 1-75] after the last PEMBRO dose, 3 [5%] pts progressed (after 9, 14 and 15 wks). PEMBRO was reintroduced in 1 patient resulting in a CR. The median time on treatment of the 26 pts who stopped PEMBRO due to an AE in the absence of PD was 27 wks [range 1-103]. Their BORR was 77% [9 [35%] CR, 11 [42%] PR, 5 [19%] SD, 1 [4 %] NE]. After a median follow-up of 50 wks [range 12-109] following the last PEMBRO dose, 9 [35 %] pts progressed. Median time to PD was 26 wks [range 7-108]. PD was not correlated with BOR. PEMBRO was reintroduced in 4 pts resulting in 1 CR, 1 PD, 1 SD and 1 NE. Conclusions: In this real life experience, advanced melanoma pts who discontinue PEMBRO treatment upon pt/MD decision, in the absence of PD or AE, were at low risk for short-term recurrence. Pts stopping PEMBRO due to an AE in the absence of PD (having a shorter exposure to PEMBRO and longer FU after discontinuing treatment) seem to have a higher risk for subsequent PD.
Prognostic role of plasma HER2 gene copy number in patients with HER2 positive metastatic breast cancer.
Authors: Ran Ran, Wenfa Huang, Shao Lin, Yunyun Niu, Hope S. Rugo, Weiyao Kong, Shiping Bo, Sijia Lu, Huiping Li
Journal: Journal of Clinical Oncology (2018)

e13018 Background: Only a subset of patients with HER2 positive (HER2+) metastatic breast cancer (MBC) responds to anti-HER2 therapy. This study aimed at detecting plasma HER2 gene copy number (GCN) as a prognostic factor in HER2+ MBC patients using next-generation sequencing (NGS). Methods: A total of 50 MBC patients were included in this retrospective study, 44 HER2+, and six HER2 negative (HER2-) as control. HER2 GCN in plasma either in base line or after trastuzumab treatment was detected by NGS technique. Plasma HER2 GCN of ≤2.22, > 2.22-4.0 and ≥4.0 were predefined as cut-off to classify patients into HER2 non-amplified, low or high HER2 GCN group. Results: We obtained values of plasma HER2 GCN ranging from 1.77 to 33.0 (median 2.35), with the number of patients in the three groups of 20, 16 and 14. There was higher concordance of HER2 status between plasma and metastatic tumors (kappa index = 0.289 VS. 0.167) with three HER2- MBC who were HER2- in metastatic site all in non-amplified group. The median HER2 GCN was higher in subjects with more metastatic diseases (≥ 3 sites, P < 0.001). More significant decrease of HER2 GCN was found in patients responded to trastuzumab (P = 0.037), although the objective response rate was not different according to plasma HER2 status. Kaplan-Meier survival analysis did not find a significant influence of plasma HER2 status and other patient characteristics on progression free survival (PFS), but there was a trend of shorter PFS in plasma HER2+ subjects. Patients with high HER2 GCN, more metastases (≥ 3 sites) and without anti-HER2 therapy were subjected to shorter overall survival (OS) (all P < 0.05). At the Cox regression model, there was an indication that patients who had higher plasma HER2 GCN had shorter PFS (HR = 1.095, P = 0.009) and OS (HR = 1.142, P < 0.001). Metastatic disease with ≥ 3 sites was another risk factor for OS in multivariate analysis (HR = 4.087, P = 0.011), while anti-HER2 therapy was diminished. Conclusions: We suggest that plasma HER2 gene copy number serve as a predictor of disease progression and overall survival in HER2+ MBC patients, and correlate with trastuzumab response.
Somatic mutations in homologous recombination pathway genes in ovarian cancer.
Authors: Carol Aghajanian, Deborah DeLair, Rachel N. Grisham, Martee Leigh Hensley, Jason A. Konner, Vicky Makker, Roisin Eilish O'Cearbhaill, Paul Sabbatini, Tara Soumerai, Alexandra Snyder Charen, David R. Spriggs, Robert A. Soslow, William P. Tew, Dmitriy Zamarin, Mark E. Robson, Michael F. Berger, David B. Solit, David Michael Hyman, Karen Anne Cadoo
Journal: Journal of Clinical Oncology (2017)

5545 Background: 15% of patients with OC have a germline BRCA 1 / 2 mut &amp; 6% of OC have a somatic BRCA 1/ 2 mut. Inhibitors of poly ADP ribose polymerase (PARPi) are approved in this setting. Data is evolving as to activity of PARPi in BRCA wild type OC with somatic homologous recombination (HR) gene deficiency. We sought to determine the prevalence of somatic alterations in HR genes in an unselected cohort of epithelial OC of any histologic type. Methods: From 03/2014-10/2016 patients consented to an IRB approved protocol for tumor-normal sequencing, via a custom next-generation sequencing panel (MSK-IMPACT) with return of results for tumor mut only. Muts in 14 HR genes ( ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, FANCA, MRE11, NBN, PALB2, PTEN, RAD51D, RAD51C) and p53were assessed. Statistics were analyzed using GraphPad Prism v. 6. Results: 260 tumors were sequenced; 156 (60%) high grade serous (HGS), 34 (13%) low grade serous (LGS), 34 (13%) clear cell, 10 (4%) mucinous, 8 (3%) endometrioid, 18 (7%) mixed/other histology. 151 (97%) of HGS and 24 (23%) of the remaining tumors harbored p53 mut. 48 (18%) somatic HR mut were identified. (Table 1) 26 HGS (17%) tumors and 22 (21%) of the remaining tumors harbored a HR gene mut (HGS vs other histology, p=0.4). Notably, 8 (24%) of clear cell cancers demonstrated HR gene muts (vs HGS, p=0.3). 18 (38%) of the identified muts in the overall cohort were in BRCA 1/2. There were no somatic HR gene muts identified in the mucinous OC, which were characterized by frequent p53 (90%) and KRAS(60%) muts. Conclusions: In this cohort of OC, 17% of tumors harbor somatic HR gene muts. The prevalence of HR somatic muts was similar in HGS vs other histologies, with the exception of mucinous OC. BRCA1/2 muts predominated, however 60% of identified muts were in other genes. Accrual is ongoing to increase histologic cohort sizes. Broad HR gene somatic mutational profiling may identify a wider cohort of OC patients with potential to benefit from PARPi therapy. [Table: see text]
Vimentin expression in lymph node metastatic lesions of squamous cell carcinoma of the esophagus.
Authors: Hiroyuki Jin, Kenichi Hakamada
Journal: Journal of Clinical Oncology (2016)

e15547 Background: Squamous cell carcinoma of the esophagus (ESCC) still has a poor prognosis. We previously reported that vimentin expression in the primary tumor of ESCC correlates with lymph node metastasis. We also reported that vimentin expression is observed at a high frequency in lymph node metastatic lesions in patients with vimentin-positive primary tumors (Jin H, et al. Biomed Res. 31(2): 105-112, 2010). Since the clinical significance of vimentin expression has not been sufficiently examined, we studied its associations with clinicopathological factors. Methods: The subjects were 120 patients with ESCC who had undergone curative resection without preoperative treatment at Hirosaki University Hospital between 1996 and 2008. Vimentin expression was evaluated immunohistochemically in primary tumors and lymph node metastases, and correlations with clinicopathological factors were examined. Results: Vimentin expression was detected in 74.2% (89/120) of primary tumors. Similar to a pervious study, the incidence of lymph node metastasis was 71.9% (64/89) in the vimentin-positive group, higher than that in the negative group (35.5 % [11/31]) (P = 0.0004). However, the 5-year overall survival rate in patients with vimentin-positive primary tumors was 54.8%, not different from that in the negative group (59.7%) (P = 0.9020). The incidence of lymph node metastasis was 62.5% (75/120). Vimentin expression was noted in lymph node metastatic lesions in 60% (45/75) of patients with lymph node metastasis. The 5-year overall survival rate for patients with vimentin-positive lymph node metastatic lesions was 42.9%, significantly poorer than that of the negative group (66.1%) (P = 0.0167), whereas the 5-year survival rate for patients with vimentin-negative lymph node metastatic lesions was similar to that of patients without lymph node metastatic lesions (67.9%) (P = 0.7320). The 5-year recurrence-free survival rate was also poorer in patients with vimentin-positive (52.0%) than in those with vimentin-negative (33.8%) lymph node metastatic lesions (P = 0.0499). Conclusions: Vimentin expression in lymph node metastatic lesions of ESCC may be a prognostic factor, i.e. a predictor of recurrence.
Chemotherapy and cognitive function in testicular cancer: A prospective, longitudinal cohort study.
Authors: Ian N. Olver, Hayley S. Whitford, Pawel Kalinowski, Adrian Schembri, Guy C. Toner, Martin R. Stockler, Andrew James Martin, Ian D. Davis, Peter S. Grimison
Journal: Journal of Clinical Oncology (2016)

4547 Background: Neuropsychological assessments suggest chemotherapy may lead to cognitive impairment but causal links remain unclear. Methodological limitations can be addressed by prospective longitudinal studies using different chemotherapy regimens, appropriate controls and adjusting for confounders. Methods: This 16 centre, prospective longitudinal observational study accrued 145 patients with testicular cancer and analysing those with sufficient data, compared 2 groups, surgery only (n = 41) and surgery + chemotherapy (n = 61). Cognition was assessed by CogHealth, a 10-minute online playing-card tool that overcomes language limitations, assessment burden, and practice/ceiling effects. Quality of life, fatigue, anxiety, depression and self-perceived cognitive function were also assessed. Linear mixed models were used to compare changes in scores from baseline ( ≤ 6 months after orchidectomy and before chemotherapy) and follow-up (12-18 months later). Results: There were no significant differences between the 2 groups from baseline to follow-up across the cognitive tasks; complex decision-making, visual learning, working memory or visual attention. Self-perceived cognitive function matched measured performance. However, there were significant interactions between groups (i.e. the surgery + chemotherapy group had a different trajectory over time compared to the surgery group) for psychomotor function (covarying age, p < 0.001) and for physical wellbeing (covarying radiotherapy, p = 0.008). The surgery + chemotherapy group scored significantly worse than the surgery group at baseline on psychomotor function (p = 0.03, d = -0.85), physical wellbeing (p < 0.0001, d = 0.80), fatigue (p = 0.01, d = 0.53) and anxiety (p = 0.005, d = -0.80), but there were no significant differences at follow-up. For both groups, anxiety (p = 0.03), functional (p = 0.001) and emotional wellbeing (p = 0.002) improved over time. Conclusions: For patients with testicular cancer there were no significant differences between groups for objective or self-reported cognitive function after 12 months, with only psychomotor function and physical wellbeing worse in the chemotherapy group at baseline. Clinical trial information: 12609000545268.
PTLD: Survival and analysis of prognostic factors in a cohort of 138 patients from a single institution.
Authors: Rohit Bishnoi, Ravneet Bajwa, Aaron J Franke, Niraj Patel, William Paul Skelton, William Birdsall Slayton, Fei Zou, Sican Xiong, Nam H. Dang
Journal: Journal of Clinical Oncology (2017)

e19048 Background: The outcome and prognostic factors of post-transplant lymphoproliferative disorder (PTLD) varies in currently reported literature. We present one of the largest single institution retrospective analysis from University of Florida. Methods: Patient population was identified from EMR and charts were reviewed to collect data. Primary outcome was Overall survival (OS) and secondary outcome was identification of prognostic factors. Results: We identified 138 patients with PTLD from Sept 1994 to Feb 2016 (liver 34%, Kidney 23%, heart 21%, lungs 12%, kidney-pancreas 2% and BMT 6%). After survival analysis, 131 patients were further followed for secondary outcomes. 36% (n = 47) were less than 18 years of age, 60% (n = 83) were males. The median age of PTLD diagnosis was 44 years and the median duration from transplant to PTLD was 4.4 years. Pathology was early lesion 6% (n = 8), polymorphic 17% (n = 23), Monomorphic 71% (n = 93), Hodgkin/like 4.5% (n = 6). Extra-nodal site involvement was 61% (n = 80), most common being GI tract. Ann-Arbor stage distribution was stage I/II 50% (n = 65), stage III/IV 46% (n = 60). Initial treatment was immunosuppression (IS) reduction alone in 24% (n = 31), Rituximab (R) 24% (n = 31), chemotherapy (+/- R) 46% (n = 60). Most common chemo regimen was CHOP (+/-R) 27% (N = 36). After first line, 48% patients had complete remission (CR), 18% partial remission (PR) and 15% progressive disease (PD). Second line treatment was required in 33% (n = 44) and 10% (n = 13) patients required 3 rd line treatment. Final analysis showed 61% (n = 80) achieved CR, 17% (n = 22) had PD, 56% (n = 74) patients were alive and 49% (n = 64) are alive without PTLD. Median OS was 14.99 years. Multivariate analysis identified transplant age, organ transplant recipients, PTLD diagnosis age, performance status, IPI score, graft rejection, history of malignancy and recipient EBV status as prognostic factors (p &lt; .05). Conclusions: This study from a leading regional transplant center shows notable OS which is likely from improved immunosuppressive regimens, treatment modalities and large pediatric population. We identified various prognostic factors affecting survival and propose validation to generate prognostic score.
Biodegradable hypocrellin derivative nanovesicle as a near-infrared light-driven theranostic for dually photoactive cancer imaging and therapy
Authors: Xiuli Zheng, Jiechao Ge, Jiasheng Wu, Weimin Liu, Liang Guo, Qingyan Jia, Ying Ding, Hongyan Zhang, Pengfei Wang
Journal: Biomaterials (2018)